LAM Pilot Study With Imatinib Mesylate

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Lymphangioleiomyomatosis

In brief

This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).

Key facts

Study ID
NCT03131999
Run by
Medical University of South Carolina
People needed
18
Starts
2018-01-23
Expected to finish
2019-03-07
Last updated by the study team
2020-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.